A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?

Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have become a “game-changer” in the cancer treatment. However, none of the small molecular inhibitors has been approved yet. To explore the advantages and disadvantages of various scaffolds, different biological evaluations were performed...

Ausführliche Beschreibung